Abbisko Therapeutics Co. Ltd. has announced that the United States Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for pimicotinib, a selective oral CSF-1R inhibitor, for the treatment of tenosynovial giant cell tumor. This follows the drug’s prior approval in China by the National Medical Products Administration and sets the stage for what could become one of the most closely watched U.S. rare tumor approvals of 2026. Pimicotinib is being co-developed globally through a commercial licensing partnership with Merck KGaA, Darmstadt, Germany.

While the FDA’s acceptance does not imply approval, it affirms that Abbisko Therapeutics has submitted a review-ready dossier, supported by robust Phase III data from the MANEUVER study. As a systemic treatment option for TGCT, pimicotinib represents a possible shift away from surgery-first approaches that often carry significant risks to joint function.

Why the FDA filing signals a pivot in how rare tumors like TGCT are clinically evaluated

The regulatory acceptance of pimicotinib’s application is not just a procedural milestone. It reflects evolving clinical and regulatory consensus around what constitutes meaningful outcomes in the treatment of rare, locally aggressive tumors such as tenosynovial giant cell tumor. Unlike many cancers where survival metrics dominate, TGCT is non-metastatic and primarily impairs quality of life through joint pain, stiffness, swelling, and loss of mobility.

The MANEUVER trial placed a strong emphasis on patient-reported outcomes and functional endpoints, in addition to radiographic response. Objective response rate was the primary endpoint, assessed by a blinded independent review committee using RECIST v1.1 at Week 25. But secondary endpoints such as improvement in stiffness, pain reduction, physical function, and range of motion were also statistically and clinically significant.

This multi-pronged endpoint strategy suggests that regulators, especially in the United States and Europe, are more willing to accept functional gains and quality-of-life metrics as the clinical foundation for approval in non-lethal tumor types. Industry analysts expect this paradigm to shape future trial designs for similar indications, where tumor burden may be less critical than physical capability or symptom control.

How pimicotinib compares with existing CSF-1R therapies like pexidartinib

The CSF-1R inhibitor landscape remains thin, with pexidartinib as the most notable precedent. Developed by Daiichi Sankyo, pexidartinib was approved by the U.S. Food and Drug Administration for TGCT under a Risk Evaluation and Mitigation Strategy due to hepatotoxicity risks. This boxed warning and restricted distribution limited its uptake despite being the first systemic therapy approved for the indication.

Pimicotinib’s clinical profile may offer a cleaner safety window. With no REMS designation required at this stage, and longer-term data from 14.3-month follow-ups suggesting durability without new safety concerns, pimicotinib appears poised to challenge pexidartinib’s incumbency. However, no direct comparison trial has been conducted between the two molecules.

Abbisko Therapeutics has stressed the high selectivity and potency of pimicotinib as key differentiators. Preclinical data and biomarker work have also pointed to fewer off-target effects. If confirmed by the full review, this may allow pimicotinib to secure a broader label, especially in patients with earlier-stage or functionally at-risk tumors.

What the Merck KGaA alliance adds to pimicotinib’s global prospects

Abbisko Therapeutics’ out-licensing of pimicotinib to Merck KGaA represents a defining move in the global trajectory of the drug. While Abbisko retains rights within Greater China, Merck now leads development, registration, and commercialization efforts across other geographies. The collaboration not only signals external validation of the drug’s scientific promise but also bolsters its global market potential through Merck’s oncology infrastructure and commercial experience.

The strategic partnership could become a case study in cross-border oncology co-development. For Merck, pimicotinib offers a foothold in a rare tumor niche with limited systemic competition and a fast-track regulatory path. For Abbisko Therapeutics, it validates the ability of a China-originated molecule to meet global standards, potentially paving the way for future international collaborations.

In addition to U.S. regulatory progress, the drug has secured PRIME designation from the European Medicines Agency, which allows for early and intensified dialogue with regulators. This, combined with the FDA’s Breakthrough Therapy Designation, gives pimicotinib one of the strongest expedited regulatory support packages seen in recent years for a rare tumor therapy.

What risks still surround the regulatory review and commercial execution

Despite the clear regulatory momentum, several areas of uncertainty could affect pimicotinib’s path to market. Chief among them is the FDA’s final stance on long-term safety. Although the pivotal trial showed encouraging tolerability, real-world usage could surface adverse effects not seen in trial settings. A worst-case scenario involving liver safety concerns, even at low incidence, could bring restrictions similar to pexidartinib’s, limiting broad deployment.

Another challenge lies in market access and reimbursement. TGCT is rare, but treatment may be prolonged or even indefinite, depending on recurrence risk and symptom control. Payers may hesitate to reimburse chronic use of an expensive oral therapy, especially in cases where surgery remains a viable, if invasive, alternative.

Adoption among orthopedic oncologists is also not guaranteed. While systemic therapy offers non-surgical patients a new option, many TGCT cases are still managed surgically. Changing entrenched clinical practice will require not only efficacy but a compelling economic and functional case. Market penetration may hinge on Abbisko and Merck’s ability to educate physicians and align with orthopedic treatment pathways, especially in Europe and the United States.

Why this matters for Chinese biopharma’s global credibility

Beyond its impact on TGCT, the pimicotinib story holds symbolic weight for the Chinese biotech sector. Abbisko Therapeutics becomes one of the few oncology-focused Chinese firms to bring a wholly self-developed asset to FDA review with the backing of a global pharmaceutical partner. This milestone may encourage more Chinese-originated drug developers to pursue multinational trials, dual-track regulatory strategies, and out-licensing models with top-tier global players.

Historically, Chinese biotech firms have excelled in biosimilars and generic exports but have struggled to deliver innovative, globally approved assets. Pimicotinib’s potential approval in the United States would challenge that trend and showcase the maturing clinical development and regulatory capabilities emerging from China’s biotech hubs, especially Shanghai.

Industry observers note that such breakthroughs are likely to accelerate venture interest, cross-border licensing, and multinational clinical trial infrastructure in Asia. If successful, pimicotinib could be a first-of-its-kind molecule that validates China’s transition from follower to contributor in the global innovation pipeline for oncology.

What to expect as the pimicotinib review advances

All eyes will now be on the U.S. regulatory clock, with a decision expected in the second half of 2026. Assuming no major review delays, approval could arrive within the year. A positive outcome would likely trigger rapid market launches across Europe, Japan, and other priority jurisdictions where regulatory filings are either underway or imminent.

Merck’s launch strategy will be under close watch. Key priorities will include building awareness among surgical and oncology communities, securing payer agreements for first-line use in nonsurgical candidates, and integrating pimicotinib into guideline development. Real-world evidence generation and safety tracking will also be essential, especially if Merck seeks broader label expansion or combination studies in future tumor types driven by CSF-1R overexpression.

Should the FDA raise new safety questions or require a REMS program, the commercial outlook would narrow. However, early signals suggest that pimicotinib is positioned to become the preferred systemic TGCT option if approved. Much will depend on how well Merck and Abbisko translate clinical trial results into post-approval data that demonstrate functional benefits and long-term tolerability in real-world patients.

  Abbisko Therapeutics, CSF-1R inhibitor, FDA NDA, Merck KGaA, oncology, pimicotinib, rare tumors, tenosynovial giant cell tumor, TGCT